Table 2. Kaplan-Meier Estimates of Clinical Outcomes at 5 Years for Patients With a Recurrence Score of 26 to 100 Assigned to Chemotherapy Stratified by Adjuvant Chemotherapy Regimen in the Intention-to-Treat Populationa.
Variable | Mean (SE) [95% CI] | ||||||
---|---|---|---|---|---|---|---|
All Patients | Taxane and Cyclophosphamide | Anthracycline Without Taxane | Anthracycline and Taxane | CMF | Other | No Chemotherapy | |
No. | 1389 | 589 | 334 | 244 | 52 | 81 | 89 |
Invasive disease-free survival | 87.6 (1.0) [85.5-89.4] | 88.1 (1.5) [84.8-90.8] | 87.4 (2.0) [83-90.8] | 88.6 (2.3) [83.2-92.3] | 84 (5.6) [69.3-92.1] | 91.3 (3.4) [81.5-96] | 79.7 (4.9) [67.9-87.5] |
Freedom from recurrence of breast cancer at a distant site | 93.0 (0.8) [91.4-94.4] | 92.7 (1.2) [90-94.7] | 92.3 (1.6) [88.5-94.9] | 95.1 (1.5) [91-97.3] | 88.5 (4.8) [74.6-95.1] | 95.5 (2.5) [86.8-98.5] | 92.8 (3.1) [83.6-97] |
Freedom from recurrence of breast cancer at a distant or local-regional site | 91.0 (0.8) [89.1-92.5] | 91.0 (1.3) [88-93.2] | 90.1 (1.8) [86-93] | 93.6 (1.7) [89.1-96.2] | 88.7 (4.8) [74.9-95.1] | 95.5 (2.5) [86.8-98.5] | 84 (4.5) [72.8-90.8] |
Overall survival | 95.9 (0.6) [94.6-96.9] | 95.8 (0.9) [93.6-97.2] | 96.7 (1.0) [93.9-98.2] | 97.2 (1.1) [93.8-98.7] | 90.1 (4.7) [75.8-96.2] | 97.2 (2.0) [89.2-99.3] | 90.7 (3.7) [80.3-95.7] |
Abbreviation: CMF, cyclophosphamide/methotrexate/5-fluorouracil.
Five-year Kaplan-Meier estimates (percent), standard error, and 95% confidence intervals shown.